Japan-based Solasia Pharma has entered into a licensing agreement with Firebird Biologics (headquartered in Singapore) granting exclusive rights for the sales and distribution of the anti-tumour drug DARVIAS (generic name: darinaparsin) and the medical device Episil (intended for the management and relief of oral pain caused by chemotherapy- or radiation therapy- induced oral mucositis) across 19 countries in Southeast Asia, Oceania, Middle East, and Africa.
Under the terms of the agreement, a licensing deal has been established to facilitate the commercialisation and marketing of products in the territories of Asia including Australia & New Zealand, the Middle East, and Africa by Firebird Biologics.
Solasia has also announced that Firebird Biologics has obtained sales approval for episil from Singapore authorities, started preparations for sales activities, and that product supply from Solasia to Firebird is initiated.
